Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

Published:2017-11-01 Issue:11 Volume:177 Page:1569
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Prasad Vinay¹²³,Mailankody Sham⁴⁵

Affiliation:

1. Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland

2. Department of Preventive Medicine and Public Health, Oregon Health and Science University, Portland

3. Center for Health Care Ethics, Oregon Health and Science University, Portland

4. Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

5. Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Reference27 articles.

1. Five years of cancer drug approvals: innovation, efficacy, and costs.;Mailankody;JAMA Oncol,2015

2. The high price of anticancer drugs: origins, implications, barriers, solutions.;Prasad;Nat Rev Clin Oncol,2017

3. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.;Experts in Chronic Myeloid Leukemia;Blood,2013

4. In support of a patient-driven initiative and petition to lower the high price of cancer drugs.;Tefferi;Mayo Clin Proc,2015

5. Innovation in the pharmaceutical industry: new estimates of R&D costs.;DiMasi;J Health Econ,2016

Cited by 322 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach;Research Policy;2024-10

2. Can Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?;Journal of Medicinal Chemistry;2024-09-10

3. Why is the market design for innovative pharmaceuticals not well understood?;Journal of Comparative Effectiveness Research;2024-09-10

4. Exploring the potential of two Pseudomonas species to produce vincristine from vinblastine via biotransformation;Scientific Reports;2024-08-23

5. Combination of Indomethacin with Nanostructured Lipid Carriers for Effective Anticancer Therapy;International Journal of Nanomedicine;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3